AuTologous Wound Therapy, Inc. Announces Completion of $6,500,000.00 Private Placement of Common Stock.Business Editors LITTLE ROCK, Ark.--(BUSINESS WIRE)--March 9, 2000 AuTologous autologous /au·tol·o·gous/ (aw-tol´ah-gus) related to self; belonging to the same organism. au·tol·o·gous adj. 1. Wound Therapy, Inc. announced today that they have completed a private equity placement of common stock in the amount of $6,500,000.00. The financing will be used for expanding operations and increasing potential market penetration Noun 1. market penetration - the extent to which a product is recognized and bought by customers in a particular market penetration - the act of entering into or through something; "the penetration of upper management by women" of the AuTolo(TM)-Cure Program. AuTologous Wound Therapy, Inc. is focused on the chronic wound care market, and provides the AuTolo(TM)-Cure Process through licensed AuTolo-Cure Program facilities. Under the program, hospitals, wound care centers and private practice facilities are trained and licensed in the production of AuTolo(TM)-Gel, a proprietary autologous tissue coagulum coagulum /co·ag·u·lum/ (ko-ag´u-lum) pl. coa´gula [L.] clot (1). co·ag·u·lum n. pl. co·ag·u·la 1. A clot; a curd. 2. for treating chronic nonhealing wounds such as; diabetic foot diabetic foot A foot with a constellation of pathologic changes affecting the lower extremity in diabetics, often leading to amputation and/or death due to complications; the common initial lesion leading to amputation is a nonhealing skin ulcer, induced by ulcers, venous stasis venous stasis Medtalk The pooling of venous blood in a particular region which, in the legs results in edema, hyperpigmentation and possibly ulceration wounds and pressure ulcers Pressure ulcer Also known as a decubitus ulcer, pressure ulcers are open wounds that form whenever prolonged pressure is applied to skin covering bony outcrops of the body. Patients who are bedridden are at risk of developing pressure ulcers. . This release contains certain forward-looking statements regarding future events and developments affecting the business of AuTologous Wound Therapy, Inc. These forward-looking statements involve known and unknown risks, uncertainties or other factors not under the control of Autologous Wound Therapy, Inc. which may cause actual results, performance, achievements or other expectations expressed or implied by these forward-looking statement. For more information regarding AuTologous Wound Therapy, Inc. and the AuTolo-Cure Program, please contact; Mr. Rick Langhammer at 501-228-0880 or Mr. Charles Worden at 501-225-8400. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion